APOLLOMICS
Apollomics is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including the novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.
APOLLOMICS
Industry:
Biotechnology Health Care Oncology Pharmaceutical
Founded:
2016-01-01
Address:
Foster City, California, United States
Country:
United States
Website Url:
http://www.apollomicsinc.com
Total Employee:
11+
Status:
Active
Contact:
+1-650-209-4055
Total Funding:
262.6 M USD
Technology used in webpage:
SPF IPv6 Cloudflare Hosting Cloudflare DNS Intermedia
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
New Century Pharmaceuticals
New Century Pharmaceuticals, Inc. is a biopharmaceutical company with an Oncology and Anti-infective focus which uses leading expertise.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Ping An Capital
Ping An Capital investment in Series C - Apollomics
WR Hambrecht
WR Hambrecht investment in Series C - Apollomics
CMB International Capital Corporation
CMB International Capital Corporation investment in Series B - Apollomics
Junson Capital
Junson Capital investment in Series B - Apollomics
Guangzhou Yue Min Investment
Guangzhou Yue Min Investment investment in Series B - Apollomics
OrbiMed
OrbiMed investment in Series B - Apollomics
K2VC
K2VC investment in Series B - Apollomics
South China Venture Capital
South China Venture Capital investment in Series B - Apollomics
Pan-Lin Capital
Pan-Lin Capital investment in Series B - Apollomics
OrbiMed
OrbiMed investment in Series A - Apollomics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-01-17 | MabPlex International | Apollomics investment in Series A - MabPlex International | 400 M CNY |
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-04 | Apollomics appoints CFO |
Official Site Inspections
http://www.apollomicsinc.com Semrush global rank: 3.3 M Semrush visits lastest month: 4.26 K
- Host name: 172.67.68.218
- IP address: 172.67.68.218
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Apollomics"
Our Company - Apollomics, Inc.
At Apollomics, we are a purpose-driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the … See details»
Apollomics - LinkedIn
Apollomics | 2,585 followers on LinkedIn. We are a biopharmaceutical company committed to the discovery and development of mono- and combination cancer therapies. | Apollomics is an innovative ... See details»
Apollomics, Inc. (APLM) Company Profile & Facts - Yahoo Finance
Apr 3, 2025 See the company profile for Apollomics, Inc. (APLM) including business summary, industry/sector information, number of employees, business summary, corporate governance, … See details»
Apollomics (APLM) Company Profile & Description - Stock Analysis
4 days ago Company profile for Apollomics, Inc. (APLM) stock, with a description, list of executives, contact details and other key facts. See details»
Apollomics - 2025 Company Profile & Team - Tracxn
Jun 20, 2025 Apollomics - Developer of small molecule antibody-based drugs for the treatment of cancer. Public Company. Raised a total funding of $234M over 4 rounds from 14 investors. See details»
Apollomics Inc. - A spin-out from Nottingham …
Science-driven approach powering a pipeline of next-generation, combination and pan-cancer therapies for patients globally See details»
Apollomics, Inc. - Committed to the discovery and …
Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific … See details»
Apollomics - Work in biotech
Apollomics is developing a suite of next-generation therapies to treat cancer. Developing clinical assets requires rigorous preclinical studies and mechanistic and scientific rationale whether … See details»
Apollomics Company Profile - Craft
Oct 29, 2024 Apollomics has 2 employees across 4 locations. See insights on Apollomics including office locations, competitors, revenue, financials, executives, subsidiaries and more … See details»
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed
Jan 4, 2022 The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. See details»
Apollomics (USA) Funding: $262.6M - Medical Startups
Jun 25, 2025 Apollomics is an emerging life sciences oncology company focused on developing innovative medicines targeting the growth and proliferation of cancer cells for which available … See details»
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD ... - ACN …
Jan 4, 2022 The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. See details»
Contact - Apollomics, Inc.
Contact Us Email us Investors and [email protected] Business [email protected] General [email protected] … See details»
Apollomics, Announces Closing of Business Combination and …
Mar 30, 2023 Apollomics’ Class A ordinary shares and public warrants are expected to begin trading today on the Nasdaq Capital Market under the ticker symbols ‘APLM’ and ‘APLMW’ … See details»
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as …
The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San … See details»
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as …
Nov 22, 2021 Foster City, CA, and Hangzhou, China, January 04, 2022 — Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- … See details»
Apollomics and LaunXP Announce Development and …
Mar 31, 2025 LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong … See details»
Our Approach - Apollomics, Inc.
Our Approach Apollomics is committed to the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system … See details»
Join Our Team - Apollomics, Inc.
Welcome to Apollomics, Inc. We believe that our current and future success depends on the contribution and dedication of each of our employees. We are proud to have built a strong … See details»
Pipeline - Apollomics, Inc.
Our Pipeline Our broad pipeline includes multiple targeted therapies that harness the immune system and target specific molecular pathways. Notes: IP - Intellectual Property GBM - … See details»